🔗 Share this article Users Coming Off Anti-Obesity Jabs Gain Back Weight Four Times Faster Compared to People Using Diet and Exercise Weight management involves ongoing approaches. Fresh analysis suggests that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt conventional diet and exercise plans. Findings released in a prominent medical journal points out that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit. "Individuals using such treatments need to be cognizant of the danger of quick weight regain when the therapy is stopped," warns researcher Dr. Susan Jebb. This pace of recovery implies a reversion to starting weight within about 18 months. Analyzing Treatments The research, which reviewed dozens of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods. Researchers note that people who lose weight through dieting typically see a more gradual creep back—around 100 grams monthly—post-intervention. Understanding the Quick Regain Doctors propose the mode of action of the drugs explains the heightened weight return. The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist. "Discontinuation of this hormone supplement means hunger is unsuppressed, making excessive eating a significant risk." A Chronic Issue? The NHS advise the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications. Professionals argue that, considering the likelihood of weight regain, the therapy is often ongoing. This perspective is supported by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," similar to managing conditions like hypertension. User Accounts Users who have discontinued the jabs report a sudden resurgence of cravings. "It was like a trigger activating and you become ravenous," described one woman. The struggle is exacerbated if individuals have not established permanent dietary or behavioural changes during therapy. Growing Use Figures show that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high. Adoption is greater among women compared to males. The 40s and 50s age group shows the greatest level of interest. Many obtain the drugs through private healthcare rather than public health services. Finally, clinicians stress that while the jabs are potent agents for weight loss, they are not a standalone cure and long-term success relies on ongoing behavioural changes.
Weight management involves ongoing approaches. Fresh analysis suggests that patients who stop using blockbuster weight-loss injections like semaglutide or tirzepatide can put back on shed pounds much more quickly than those who halt conventional diet and exercise plans. Findings released in a prominent medical journal points out that while obese individuals frequently drop about a fifth of their total mass while undergoing treatment, the weight returns at an average rate of 0.8 kg per month once they quit. "Individuals using such treatments need to be cognizant of the danger of quick weight regain when the therapy is stopped," warns researcher Dr. Susan Jebb. This pace of recovery implies a reversion to starting weight within about 18 months. Analyzing Treatments The research, which reviewed dozens of studies involving thousands of participants, contrasted the effects of GLP-1 agonists with older methods. Researchers note that people who lose weight through dieting typically see a more gradual creep back—around 100 grams monthly—post-intervention. Understanding the Quick Regain Doctors propose the mode of action of the drugs explains the heightened weight return. The injections mimic a natural hormone called glucagon-like peptide-1, which moderates appetite. "Artificially providing the hormone concentrations several times higher than the body's typical production may cause the body to generate a reduced amount of its endogenous hormone, and may also lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition specialist. "Discontinuation of this hormone supplement means hunger is unsuppressed, making excessive eating a significant risk." A Chronic Issue? The NHS advise the jabs for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications. Professionals argue that, considering the likelihood of weight regain, the therapy is often ongoing. This perspective is supported by drug manufacturers, who state that the findings "highlight the long-term character of excess weight," similar to managing conditions like hypertension. User Accounts Users who have discontinued the jabs report a sudden resurgence of cravings. "It was like a trigger activating and you become ravenous," described one woman. The struggle is exacerbated if individuals have not established permanent dietary or behavioural changes during therapy. Growing Use Figures show that millions of adults in the UK have used these injections in the last 12 months, with desire remaining high. Adoption is greater among women compared to males. The 40s and 50s age group shows the greatest level of interest. Many obtain the drugs through private healthcare rather than public health services. Finally, clinicians stress that while the jabs are potent agents for weight loss, they are not a standalone cure and long-term success relies on ongoing behavioural changes.